{"id":{"repo_id":"cornell","oai_identifier":"oai:ecommons.cornell.edu:1813/36040"},"canonical_url":"https://search.ndltd.org/etd/cornell/oai:ecommons.cornell.edu:1813/36040","repository":{"repo_id":"cornell","name":"Cornell University","base_url":"https://ecommons.cornell.edu/server/oai/request"},"display":{"title":"Ubiquibodies: Engineered Ubiquitin Ligases With Unnatural Substrate Specificity For Targeted Protein Silencing","abstract":"The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called \"ubiquibodies\", which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease.","abstract_html":"The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called &quot;ubiquibodies&quot;, which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease.","abstract_has_math":false,"creators":["Portnoff, Alyse"],"institution":"Cornell University","degree_name":"Ph. D., Biomedical Engineering","degree_level":"Doctor of Philosophy","degree_discipline":"Biomedical Engineering","degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":["Delisa, Matthew"],"committee_members":["Daniel, Susan","Nicholson, Linda K"],"year":2014,"date_issued":"2014-01-27","date_published":"2014-01-27","updated_at":"2026-11-19T03:17:47Z","subjects":["protein engineering","targeted proteolysis","reverse genetics"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["8442197"],"render_values":[{"text":"8442197","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1813/36040","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1813/36040","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://ecommons.cornell.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aecommons.cornell.edu%3A1813%2F36040","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.chair","label":"Chair","values":["Delisa, Matthew"]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Daniel, Susan","Nicholson, Linda K"]},{"key":"dc:creator","label":"Author","values":["Portnoff, Alyse"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-02-25T18:39:58Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-01-28T07:02:28Z"]},{"key":"dc:date.issued","label":"Date","values":["2014-01-27"]},{"key":"dc:type","label":"Dc Type","values":["dissertation or thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biomedical Engineering"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Doctor of Philosophy"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph. D., Biomedical Engineering"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Cornell University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["protein engineering","targeted proteolysis","reverse genetics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.bibid","label":"Dc Identifier Bibid","values":["8442197"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1813/36040"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"cerif:openaire","label":"Cerif Openaire","values":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"de9cf7dc-e7d4-444d-8064-9c7b0273fb43\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>Ubiquibodies: Engineered Ubiquitin Ligases With Unnatural Substrate Specificity For Targeted Protein Silencing</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2014-01-27</PublicationDate> <Authors> <Author> <DisplayName>Portnoff, Alyse</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Keyword>protein engineering</Keyword> <Keyword>targeted proteolysis</Keyword> <Keyword>reverse genetics</Keyword> <Abstract>The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called \"ubiquibodies\", which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"]},{"key":"cris:virtual.author","label":"Cris Virtual Author","values":["Portnoff, Alyse"]},{"key":"cris:virtualsource.collection","label":"Cris Virtualsource Collection","values":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"]},{"key":"dc:description.abstract","label":"Abstract","values":["The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called \"ubiquibodies\", which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease."]},{"key":"dc:description.collection","label":"Dc Description Collection","values":["Cornell Theses and Dissertations"]},{"key":"dc:format.mimetype","label":"Dc Format Mimetype","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Ubiquibodies: Engineered Ubiquitin Ligases With Unnatural Substrate Specificity For Targeted Protein Silencing"]},{"key":"dspace:entity.type","label":"Dspace Entity Type","values":["Publication"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"cerif:openaire":["<Publication xmlns=\"https://www.openaire.eu/cerif-profile/1.1/\" id=\"de9cf7dc-e7d4-444d-8064-9c7b0273fb43\"> <Type xmlns=\"https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types\">http://purl.org/coar/resource_type/c_1843</Type> <Language>en_US</Language> <Title>Ubiquibodies: Engineered Ubiquitin Ligases With Unnatural Substrate Specificity For Targeted Protein Silencing</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2014-01-27</PublicationDate> <Authors> <Author> <DisplayName>Portnoff, Alyse</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <OrgUnit /> </Publisher> </Publishers> <Keyword>protein engineering</Keyword> <Keyword>targeted proteolysis</Keyword> <Keyword>reverse genetics</Keyword> <Abstract>The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called \"ubiquibodies\", which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease.</Abstract> <Access xmlns=\"http://purl.org/coar/access_right\" > </Access> </Publication>"],"cris:virtual.author":["Portnoff, Alyse"],"cris:virtualsource.collection":["5893a6ea-7af3-41d7-abc6-04bcd26ab5df"],"dc:contributor.chair":["Delisa, Matthew"],"dc:contributor.committeemember":["Daniel, Susan","Nicholson, Linda K"],"dc:creator":["Portnoff, Alyse"],"dc:date.accessioned":["2014-02-25T18:39:58Z"],"dc:date.available":["2019-01-28T07:02:28Z"],"dc:date.issued":["2014-01-27"],"dc:description.abstract":["The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic cells and aids in regulation of cell cycle and cellular homeostasis. This robust pathway can also be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target proteins. In this work, we present a generalizable approach for protein knockdown by developing chimera proteins, called \"ubiquibodies\", which combine the activity of an E3 ubiquitin ligase with the affinity of designer binding proteins (DBPs). Specifically, we have utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with antibody mimetic binding domains to create various ubiquibodies. Next, we optimized the chimeric construct expression in E. coli and purified uAbs to test their functional activity in vitro. Ubiquibodies were evaluated for both their target binding and subsequent target ubiquitination in vitro. This was further analyzed using mass spectroscopy to determine substrate ubiquitination sites and chain linkages. Within the eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target proteins. Finally, preliminary work was performed using rational design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce autoubiquitination. From this foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection of protein function, including post-translational modifications, and the selective degradation of proteins that underlie human disease."],"dc:description.collection":["Cornell Theses and Dissertations"],"dc:format.mimetype":["application/pdf"],"dc:identifier.bibid":["8442197"],"dc:identifier.uri":["https://hdl.handle.net/1813/36040"],"dc:language.iso":["en_US"],"dc:subject":["protein engineering","targeted proteolysis","reverse genetics"],"dc:title":["Ubiquibodies: Engineered Ubiquitin Ligases With Unnatural Substrate Specificity For Targeted Protein Silencing"],"dc:type":["dissertation or thesis"],"dspace:entity.type":["Publication"],"others:access_status":["open.access"],"thesis:degree_discipline":["Biomedical Engineering"],"thesis:degree_level":["Doctor of Philosophy"],"thesis:degree_name":["Ph. D., Biomedical Engineering"],"thesis:institution_name":["Cornell University"]},"updated_at":"2026-11-19T03:17:47Z"}